COVID-19 & Psoriasis Resource Center

To assist dermatologists and the patients they serve, the IPC is collecting information from around the world on coronavirus and psoriasis. If you have a resource on COVID-19 and psoriasis to add, please submit it to IPC.

Latest news on COVID-19 & Psoriasis

PsoProtect Registry Data Update

September 13, 2021

July Update on PsoProtect Registry Data

July 12, 2021

Expert Opinion: Coronavirus disease 2019 (COVID‐19)‐associated hospitalization and mortality in patients with psoriasis: A population‐based study

July 07, 2021

New data from the PsoProtect Registry

June 01, 2021

IPC Statement on COVID-19 & PsoriasisIPC's statement provides general guidance to physicians treating psoriasis patients based on the current understanding of the impact of COVID-19 and psoriasis.

Expert Opinions

Hear from world psoriasis experts their take on the most current publications on COVID-19.

Stories from the Field View videos and read interviews from some of IPC's experts regarding the impact on psoriasis care during the COVID-19 pandemic.

Treatment GuidelinesView recommendations from professional and patient societies around the globe that have provided additional information regarding treating patients with psoriasis during the COVID-19 pandemic.

PsoProtect Registry

Help us learn more about the impact on psoriasis and COVID-19 by participating in this global registry. You can submit a case on-line.

Key Publications Review articles on COVID-19 selected by IPC's Chief Medical Officer.

IPC STATEMENT
on SARS-CoV-2 Vaccines and Psoriasis

Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.

READ FULL STATEMENT

The National Psoriasis Foundation
COVID-19 Task Force Guidance Statements

Twenty-five key recommendations for the management of patients with psoriatic disease during the COVID-19 pandemic.

READ STATEMENTS

THIS WEEKS' PUBLICATIONS ON COVID-19 & PSORIASIS

Incidence and Prognosis of COVID-19 in Patients with Psoriasis on Apremilast: A Multicenter Retrospective Cohort Study
Exacerbated systemic signs/symptoms, including respiratory distress, with SARS-CoV-2 infection (COVID-19) has been linked to a disruption in the balance of pro- and anti-inflammatory cytokines.[1] The effect of immunomodulatory therapies on the clinical course of COVID-19 remains under investigation. Limited studies report no increase in incidence of infection or risk of developing severe COVID-19 symptoms in patients with psoriasis treated with biologic agents.[2-5] Apremilast is an oral...

Obesity - A Risk Factor for Psoriasis and COVID-19
Obesity is a major health problem whose well-known association with psoriasis has been amply described. The importance of obesity as a risk factor for poor prognosis in the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 infection has recently been demonstrated. This review examines a possible relationship between obesity, psoriasis, and COVID-19, analyzing the pathophysiological links and their practical implications. On the one hand, a higher body...

Pustular psoriasis flare-up in a patient with COVID-19
CONCLUSIONS: Our case report brings awareness to clinicians for the possible cutaneous manifestation of COVID-19, which should be considered part of the differential diagnoses.

Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
No abstract

Pediatric COVID-19 patient with exacerbated generalized pustular psoriasis
No abstract

VIEW ALL ON PUBMED

RECOURCES FROM OUR INDUSTRY PARTNERS

AbbVie
Amgen
Novartis
UCB